Literature DB >> 28275024

Levetiracetam-induced eosinophilic pneumonia.

Aisling Fagan1, Jonathan Fuld1, Elaine Soon2.   

Abstract

Levetiracetam is widely regarded as a benign antiepileptic drug, compared to older antiepileptic medication. We report a case of eosinophilic pneumonia due to levetiracetam use in a non-smoking woman aged 59 years with no previous respiratory history. Our patient presented with exertional breathlessness and marked desaturation on exertion. She displayed 'reverse bat-wing' infiltrates on her chest radiograph and peripheral eosinophilia on a complete blood count. Her symptoms, radiology and peripheral eosinophilia resolved completely with cessation of levetiracetam and a course of prednisolone. This is the first report of isolated eosinophilic pneumonia due to levetiracetam. Other reports of levetiracetam-induced eosinophilia describe drug rash, eosinophilia and systemic symptoms (DRESS syndrome). Detection of pulmonary drug reactions requires a careful drug history and high index of suspicion. Identifying and reporting a causative agent is crucially important, as cessation of the drug is essential for resolution of the syndrome. 2017 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28275024      PMCID: PMC5353476          DOI: 10.1136/bcr-2016-219121

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

Review 1.  Levetiracetam Mechanisms of Action: From Molecules to Systems.

Authors:  Itzel Jatziri Contreras-García; Noemí Cárdenas-Rodríguez; Antonio Romo-Mancillas; Cindy Bandala; Sergio R Zamudio; Saúl Gómez-Manzo; Beatriz Hernández-Ochoa; Julieta Griselda Mendoza-Torreblanca; Luz Adriana Pichardo-Macías
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

2.  Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.

Authors:  Zhan-Miao Yi; Cheng Wen; Ting Cai; Lu Xu; Xu-Li Zhong; Si-Yan Zhan; Suo-Di Zhai
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-17       Impact factor: 2.570

3.  Efficacy of levetiracetam in the treatment of pediatric epilepsy: A protocol for systematic review and meta-analysis.

Authors:  Qiming Pang; Bangtao Li; Suli Zhang; Jiaoyang Li; Shuo Gu
Journal:  Medicine (Baltimore)       Date:  2022-02-25       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.